However, in the near future, definitive overall survival data of FLAURA 2 and MARIPOSA trials may be reported and possibly change our views and give more precise suggestions on the first- and, as a consequence, also on the second-line standard treatments of advanced EGFR mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.